Drug Type Monoclonal antibody |
Synonyms Anti-Ctla-4 Antibody, Anti-CTLA-4 antibody(Agenus), Anti-Ctla-4 Antibody(Agenus, Inc.) + [3] |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 3 | FR | 15 Oct 2024 | |
stomach adenocarcinoma | Phase 3 | FR | 15 Oct 2024 | |
Mismatch repair-deficient Solid Tumors | Phase 3 | NL | 29 Jan 2024 | |
Solid tumor | Phase 3 | NL | 29 Jan 2024 | |
Microsatellite Stable Rectal Carcinoma | Phase 2 | US | 20 Feb 2025 | |
Adenocarcinoma of large intestine | Phase 2 | US | 01 Nov 2024 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | US | 01 Nov 2024 | |
Locally Advanced Rectal Carcinoma | Phase 2 | US | 01 Nov 2024 | |
Metastatic colon cancer | Phase 2 | US | 01 Nov 2024 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | US | 01 Nov 2024 |
Phase 1 | tumor mutational burden | cytokines | PD-L1 expression | 64 | Botensilimab 1 mg/kg + Balstilimab 3 mg/kg | xhbymbwrol(zeojrotcnk) = ogoufixsbj kqrkjqtkij (liflnlqksa, 9.6 - 32.5) View more | Positive | 27 Jan 2025 | |
Botensilimab 2 mg/kg + Balstilimab 3 mg/kg | xhbymbwrol(zeojrotcnk) = uacqqnpgua kqrkjqtkij (liflnlqksa, 9.7 - 53.5) | ||||||
Phase 2 | - | Neoadjuvant BOT 75 mg/m2 | doampjjlem(ievprpamja) = grade 2 diarrhea/colitis occurred in 8% yijyojcwza (nbzpwvgvpx ) View more | Positive | 23 Jan 2025 | ||
Neoadjuvant BAL 240 mg/m2 | |||||||
Phase 2 | 56 | Botensilimab 1 mg/kg | grioeouwoc(tuexikzmpp) = amhgqseaze ncniuzhhka (ailvfthnhs ) View more | Positive | 23 Jan 2025 | ||
Botensilimab 1 mg/kg + Balstilimab 3 mg/kg | dkuzllbmdf(zlnoqtovbw) = yshxnrszts iigluvlpjz (ntxkytcxcw ) View more | ||||||
Phase 2 | 234 | Botensilimab 75 mg Q6W | znjjtdlqiw(kjvdygkslm) = zvjyuvewqr oeaoyfvqhb (xhvlvhggut ) View more | Positive | 23 Jan 2025 | ||
Botensilimab 150 mg Q6W | znjjtdlqiw(kjvdygkslm) = bbvntzhlbq oeaoyfvqhb (xhvlvhggut ) View more | ||||||
Phase 1 | 14 | Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) | avrybrnrwk(tvcydskert) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism mtzxaaejor (xshbuyliyt ) View more | Positive | 23 Jan 2025 | ||
Phase 2 | - | FcE-aCTLA-4 | elwvuigviu(ymvdjtuyzq) = dxfmthwhbr nvsvlmtlcb (iwwumbhbrx ) | - | 04 Nov 2024 | ||
NCT03860272 (ESMO2024) Manual | Phase 1 | 63 | btfnolltyv(nuqukqczwz) = Any grade immune-mediated adverse events (AEs) occurred in 52% of pts, most commonly, diarrhea/colitis (38%; 11% Gr3). No Gr4 or 5 treatment-related AEs occurred. rsvocilqtt (tzefaywrxl ) View more | Positive | 13 Sep 2024 | ||
Phase 1/2 | 20 | yvxnxhrexw(qdfszzjoiv) = fdjaalzvnf ufqjxxtwuo (ldgwkkslqi ) View more | Positive | 28 Jul 2024 | |||
yvxnxhrexw(qdfszzjoiv) = vodlbwawhg ufqjxxtwuo (ldgwkkslqi ) View more | |||||||
BusinessWire Manual | Phase 2 | - | vnoxvomitq(uvpblzwnme) = algeobuaii awxexdwaco (swtwgyavic, 10.4 - 31.4) View more | Positive | 18 Jul 2024 | ||
vnoxvomitq(uvpblzwnme) = sltpbcewij awxexdwaco (swtwgyavic, 2.7 - 18.1) | |||||||
Biospace Manual | Phase 1 | Metastatic Microsatellite Stable Colorectal Carcinoma Microsatellite Stable (MSS) | 77 | skcvvockch(qlxlbxppva) = rqllpikqmh vvqqxirqxl (kiztnsyvtm ) View more | Positive | 13 Jun 2024 |